Haichang Bio's Party Branch Honored Again as 'Five-Star Party Organization', Demonstrating Achievements of Party-Led Development

Apr 27, 2025 14:26 CST Updated 14:26

Haichang Biotech

Innovative Formulation Developer

Party Building Promotes Development

April 25, 2025, inThe Two-New Party Organization Secretary's Report on Party Building Work at the Hangzhou Medicine Port Party Working Committee MeetingHaichang Biotech's Party Branch (hereinafter referred to as: Haichang Biotech Party Branch) has once again been awarded the honorary title of "Five-Star Party Organization" for its solid achievements in party building and innovative practices led by party building. This is the second consecutive year that Haichang Biotech Party Branch has received this honor, and its working model of "promoting development through party building and strengthening party building through development" has been recognized by higher-level party organizations.

Party Building Leads to Development, Original Aspiration Illuminates the Journey

As a key biopharmaceutical enterprise in Hangzhou Medicine Port, the Haichang Biotech Party Branch has consistently integrated party building with enterprise development, exploring a distinctive path of "red engine driving innovation." Party members have taken the lead in critical areas such as research and development, production quality control, and clinical trials, promoting breakthroughs in multiple core technologies and accelerating the implementation of the company’s high-end complex injectables and nucleic acid innovative drug product portfolio.

Presentation Conference Showcases Achievements, Innovation Practices Demonstrate Results

At the Annual Report Meeting, Jiang Lin, Secretary of the Haichang Biotech Party Branch, provided a detailed report on the branch's work for 2024. The branch has consistently adhered to party building as its guiding principle, integrating party work with enterprise development.

Strengthening organizational development and consolidating ideological foundations.Core to empowering enterprise development through party building, we promote the two-way cultivation of business backbones and party members, closely integrating party building with enterprise operation management, providing a solid organizational guarantee and talent support for the innovative development of the enterprise.

The Inheritance of Red Genes Empowers Enterprise Development.By participating in various learning activities organized by the Qiantang District and the Medical Port Party Working Committee, the party spirit and revolutionary spirit of the members are continuously strengthened.In November 2024, the management and Party members of Haichang Biotech went to Jinggang Mountain together to participate in a red education training program, drawing wisdom and strength from revolutionary predecessors. This was not only a profound spiritual cleansing for each participant but also a comprehensive tempering and elevation of Haichang Biotech's team cohesion and combat effectiveness. The strategic meeting held on Jinggang Mountain focused on multiple key areas such as the company’s future development direction, technological innovation pathways, and market expansion strategies, painting a vivid and vibrant picture of the company’s future blueprint.

Building a Vibrant Party Building, Promoting Enterprise Innovation and Development.In 2024, Haichang BiotechActive BranchParticipateMultiple in Qiantang DistrictTimeParty Branch Joint Construction Activities，With various branches in the regionJointly signed a party-building cooperation agreement. This initiative not only strengthened the exchange and communication between branches but also promoted in-depth cooperation in party building., alsoInjecting new vitality into the development and innovation of enterprises.

Words of Encouragement from Superiors Inspire the Journey; Pressing Forward to Write a New Chapter

Liu Guojuan, Member of the New District Working Committee, Standing Committee Member of the District Committee, Minister of Publicity Department, and Secretary of the Party Working Committee of Hangzhou Medical Port, emphasized in her comments：“Haichang Biotech Party Branch holds itself to high standards in terms of ideological guidance, base construction, and role performance.Has accumulated experience worth learning from.. Especially, the active integration of party building work into the innovative practice of the biopharmaceutical industry chain; the党员科研团队 in the clinical trials of small nucleic acid innovative drugs and the international development of 白紫 in China, the US, and Europe.Demonstrated the exemplary role`, providing a useful reference for other two-new organizations in the park.`。”

Looking Forward to the Future, Planning a New Chapter: Continuing the Blueprint

HaichangHaichang Biotech's Party Branch Retains "Five-Star Party Organization" Title: A Recognition of Standardized Construction and Effective Integration of Party Building with Business Operations. Looking ahead, the Party branch will continue to promote the spirit of "red engine driving innovation" with greater enthusiasm and solid work style, elevating both Party building and enterprise development to new heights. The branch will keep innovating its Party building model, energizing the organization, deepening co-building efforts in Party work, and contributing more significantly to the creation of a life-health science and technology innovation hub, leading the company’s high-quality development through high-standard Party building.

About Haichang Biotech

Haichang Biotech, located in the China Medicine Port in Hangzhou, is a national-level specialized and innovative "little giant" enterprise that integrates research and development, production, and sales, with biopharmaceutical technology innovation as its core driving force. Upholding the core values of "sharing, progress, truth-seeking, and pragmatism," the company focuses on the technical development and industrial application of drug delivery systems. Its product pipeline covers multiple fields, including anti-cancer, cancer immunotherapy, pain relief, and infectious disease prevention.

Haichang Biotech's self-developed QTsome® technology platform has successfully broken through the international patent barriers of nucleic acid delivery systems, overcoming key "bottleneck" technologies. HC0301, a small nucleic acid innovative drug for primary liver cancer developed based on this platform, has entered Phase II of international multi-center clinical trials in China and the United States, becoming one of the fastest progressing pipelines in the global field of precise small nucleic acid tumor treatment. In the high technical barrier and high value-added complex injectables sector, the company's core product, albumin-bound paclitaxel for injection, has been approved for marketing in nearly 40 countries including China, the EU, and the UK. It is the first Chinese R&D enterprise to obtain EU marketing authorization through centralized review, with two production sites simultaneously passing EU GMP inspections, leading the trend of "going overseas" for high-end formulations. HC016 Lipid Complex Injection, the world’s first TLR9 agonist based on lipid nanoparticle (LNP) delivery technology, has received IND approval from both China and the U.S. HC009, an mRNA COVID-19 vaccine booster, has received clinical approval from the U.S. FDA, making it the first Chinese mRNA vaccine product to gain clinical approval in the United States. The company has also received support from the “National Development and Reform Commission’s 2024 First Batch Project for Innovation and Application Demonstration of Key Products in Biomanufacturing,” reflecting its technological accumulation and industrialization capabilities in the fields of small nucleic acid innovative drugs and complex formulations.